Clinical trial
Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in…
NCT00368251 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00368251 |
|---|---|
| Title | Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults |
| Official title | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥ 16 Years) With Genetically Ascertained Unverricht-Lundborg Disease |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Unverricht-Lundborg Disease |
| Intervention type | Drug, Other |
| Interventions | Placebo, BRV 2.5 mg, BRV 25 mg, BRV 50 mg |
| Enrollment | 56 |
| Start date | Nov 1, 2006 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Aug 24, 2006 |
| Last update posted | May 31, 2023 |
| Countries | Canada, Finland, France, Israel, Russia, Serbia, Tunisia, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: